SCHEMBL3498992

SCHEMBL3498992

COc1ccc(C=Cc2ccc3nc(C(=O)O)cn3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.50
XDH P47989 1/20 0.47
THRB P10828 1/20 0.47
ATM Q13315 1/20 0.47
KDM4E B2RXH2 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PKM P14618 1/20 0.45
RELA Q04206 2/20 0.45
CYP3A4 P08684 2/20 0.45
BCHE P06276 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
F3 P13726 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
PTGS1 P23219 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3499952 0.86 PTGS1 (0.49) EGLN1KDM4ENPC1RAB9ACYP3A4
SCHEMBL3499950 0.86 PTGS1 (0.49) EGLN1KDM4ENPC1RAB9ACYP3A4
SCHEMBL3499344 0.85 KDM4E (0.57) EGLN1KDM4ENPC1RAB9AALDH1A1
SCHEMBL3500261 0.85 PTGS1 (0.58) EGLN1KDM4ENPC1RAB9ACYP3A4
SCHEMBL3500264 0.85 PTGS1 (0.58) EGLN1KDM4ENPC1RAB9ACYP3A4
SCHEMBL20705174 0.84 EGLN1 (0.54) EGLN1KDM4ENPC1RAB9APTGS1
SCHEMBL3498990 0.80 KDM4E (0.47) XDHTHRBATMKDM4ENPC1
SCHEMBL24247797 0.77 PTGS1 (0.54) EGLN1KDM4ENPC1RAB9ACYP3A4
SCHEMBL3498385 0.74 KDM4E (0.56) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3498388 0.74 KDM4E (0.56) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 EGLN1 1231/4885XDH 4302/4885THRB 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.